Pharmaceutical Executive
Industry experts weigh in on what could be the resolution of a long saga.
Pharmaceutical Executive-04-12-2006
Pharmaceutical Executive
Psychiatrists offer insight on the second phase of results from a National Institutes of Health study comparing different anti-psychotic drugs.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: FDA Approves Novo Nordisk's Rybelsus and Roche’s Gazyva/Gazyvaro
2
Merck Planning $70 Billion Investment for US Expansion
3
Amazon and WeightWatchers Partner for DTC Weight Loss Medication Offerings
4
FDA Approves Tezspire as First Biologic Targeting TSLP for Chronic Rhinosinusitis With Nasal Polyps
5
